Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice |
| |
| Authors: | Jaime S. Horton Cadie L. Buckley Alexander J. Stokes |
| |
| Affiliation: | 1.Laboratory of Experimental Medicine; John A. Burns School of Medicine; University of Hawaii; Honolulu, HI USA;2.Department of Cell and Molecular Biology; John A. Burns School of Medicine; University of Hawaii; Honolulu, HI USA;3.Center for Cardiovascular Research; John A. Burns School of Medicine; University of Hawaii; Honolulu, HI USA;4.Department of Molecular Biosciences and Bioengineering; University of Hawaii; Honolulu, HI USA;5.Chaminade University; Honolulu, HI USA |
| |
| Abstract: | Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure. |
| |
| Keywords: | TRPV1 cardiac hypertrophy apoptosis fibrosis pressure overload heart failure |
|
